When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Ayyoun is a staff writer who loves all things gaming and tech. His journey into the realm of gaming began with a PlayStation 1 but he chose PC as his platform of choice. With over 6 years of ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

I'm two for two on writing about games set on the moon today, but sometimes that's just how it is! This time around it's about a newly revealed game called Descent of Lunaris, a dungeon-crawling, turn ...

Players aren’t simply fighting to survive another descent, they’re unraveling a mystery that asks difficult questions about the nature of humanity itself. Every floor deepens the uncertainty: are you ...

It's safe to say Event Horizon: Dark Descent has been a big hit for IDW Publishing. The first two chapters of the series (which serves as a prequel to the 1997 horror movie) are both going back to ...